HRP20181570T1 - Režim doziranja spoja fgf-18 - Google Patents

Režim doziranja spoja fgf-18

Info

Publication number
HRP20181570T1
HRP20181570T1 HRP20181570TT HRP20181570T HRP20181570T1 HR P20181570 T1 HRP20181570 T1 HR P20181570T1 HR P20181570T T HRP20181570T T HR P20181570TT HR P20181570 T HRP20181570 T HR P20181570T HR P20181570 T1 HRP20181570 T1 HR P20181570T1
Authority
HR
Croatia
Prior art keywords
fgf
compound
dosage mode
dosage
mode
Prior art date
Application number
HRP20181570TT
Other languages
English (en)
Croatian (hr)
Inventor
Christoph H. Ladel
Hans Guehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20181570T1 publication Critical patent/HRP20181570T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181570TT 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18 HRP20181570T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
EP15706006.2A EP3107559B1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
HRP20181570T1 true HRP20181570T1 (hr) 2018-11-30

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20181570TT HRP20181570T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18
HRP20181572TT HRP20181572T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181572TT HRP20181572T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18

Country Status (25)

Country Link
US (2) US9724388B2 (enExample)
EP (2) EP3119417B1 (enExample)
JP (2) JP6431083B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106232622A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220773B2 (enExample)
BR (2) BR112016018685A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3107559T3 (enExample)
ES (2) ES2689071T3 (enExample)
HR (2) HRP20181570T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010871A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3107559T3 (enExample)
PT (2) PT3119417T (enExample)
RS (2) RS57709B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3107559T1 (enExample)
WO (2) WO2015124727A1 (enExample)
ZA (2) ZA201605548B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) * 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
JP7671249B2 (ja) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 変形性関節症が急速に進行するリスクがある患者の治療
KR102920449B1 (ko) * 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
CN122161846A (zh) * 2023-10-11 2026-06-05 四川至善唯新生物科技有限公司 治疗关节炎的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2006014444A1 (en) * 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
NZ574216A (en) * 2006-08-25 2011-11-25 Ares Trading Sa Treatment of cartilage disorders with fgf-18
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
AU2012232658B2 (en) * 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18

Also Published As

Publication number Publication date
RU2016137292A (ru) 2018-03-21
ZA201605548B (en) 2018-12-19
PT3119417T (pt) 2018-10-31
JP2017512194A (ja) 2017-05-18
KR102410988B1 (ko) 2022-06-17
US9889179B2 (en) 2018-02-13
AU2015220777B2 (en) 2020-10-22
LT3119417T (lt) 2018-10-25
RS57709B1 (sr) 2018-12-31
EP3107559B1 (en) 2018-07-11
KR20160116000A (ko) 2016-10-06
JP6431083B2 (ja) 2018-11-28
JP6431082B2 (ja) 2018-11-28
CN106232622A (zh) 2016-12-14
SG11201606502YA (en) 2016-09-29
BR112016018696A2 (pt) 2017-10-17
MX2016010872A (es) 2016-11-17
RU2016137289A3 (enExample) 2018-10-19
US20170072017A1 (en) 2017-03-16
LT3107559T (lt) 2018-10-25
EP3119417B1 (en) 2018-07-11
AU2015220773B2 (en) 2020-10-08
HRP20181572T1 (hr) 2018-11-30
BR112016018685A2 (pt) 2017-10-17
PT3107559T (pt) 2018-10-31
JP2017507142A (ja) 2017-03-16
CN106456713A (zh) 2017-02-22
CA2938793A1 (en) 2015-08-27
IL247083A0 (en) 2016-09-29
KR20160116001A (ko) 2016-10-06
HUE040350T2 (hu) 2019-03-28
ES2689071T3 (es) 2018-11-08
RU2016137292A3 (enExample) 2018-09-17
WO2015124727A1 (en) 2015-08-27
NZ723139A (en) 2022-12-23
AR099510A1 (es) 2016-07-27
ES2688551T3 (es) 2018-11-05
ZA201605547B (en) 2019-09-25
SG11201606505UA (en) 2016-09-29
SI3107559T1 (sl) 2018-11-30
DK3107559T3 (en) 2018-10-15
RU2691946C2 (ru) 2019-06-19
PL3107559T3 (pl) 2019-01-31
EP3119417A1 (en) 2017-01-25
AU2015220777A1 (en) 2016-09-01
IL247084A0 (en) 2016-09-29
NZ723148A (en) 2022-08-26
RU2700582C2 (ru) 2019-09-18
PL3119417T3 (pl) 2019-01-31
MX2016010871A (es) 2016-11-17
WO2015124731A1 (en) 2015-08-27
RU2016137289A (ru) 2018-03-21
US20170056474A1 (en) 2017-03-02
RS57853B1 (sr) 2018-12-31
US9724388B2 (en) 2017-08-08
AR099558A1 (es) 2016-08-03
SI3119417T1 (sl) 2018-11-30
CA2938791A1 (en) 2015-08-27
KR102410986B1 (ko) 2022-06-17
IL247084B (en) 2019-09-26
AU2015220773A1 (en) 2016-09-01
DK3119417T3 (en) 2018-10-22
IL247083B (en) 2019-09-26
EP3107559A1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
IL281863A (en) Pharmaceutical compositions comprising meloxicam
HUE047477T2 (hu) Palbociclib szilárd dózisformái
LT3197883T (lt) Nauji junginiai
LT3134402T (lt) 4-amino-imidazochinolino junginiai
HUE059158T2 (hu) Eljárás pridopidin elõállítására
HUE042964T2 (hu) Szubsztituált dihidro-izokinolinon vegyületek
DK3310231T3 (da) Doseringsindretning
HUE059694T2 (hu) Készítmény rák kezelésére
PT3298027T (pt) Compostos depsipéptidos antelmínticos
HRP20181572T1 (hr) Režim doziranja spoja fgf-18
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3363428T3 (da) Perfusionsdoseringsform
DK3283210T3 (da) Fremgangsmåde
BR112016030730A2 (pt) Composto
HUE054351T2 (hu) Vegyületek
LT3212237T (lt) Metotreksato vaistinė forma
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
IL250613B (en) Substituted bicyclic compounds
DK3597189T3 (da) Krystallinske forbindelser
IL246509A0 (en) Coordination of multiple components
DK3347403T3 (da) Polyalkoxyfedtforbindelse
IL254502A0 (en) Solid forms of menaquinols
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
HUE054584T2 (hu) Maropitant készítmény